Teprotide

A synthetic nonapeptide (Pyr-Trp-Pro-Arg-Pro-Gln-Ile-Pro-Pro) which is identical to the peptide from the venom of the snake, Bothrops jararaca. It inhibits kininase II and ANGIOTENSIN I and has been proposed as an antihypertensive agent.

Also Known As:

BPP-9a; Bradykinin-Potentiating Peptide 9a; Nonapeptide-Converting Enzyme Inhibitor; SQ-20881; Bradykinin Potentiating Peptide 9a; Enzyme Inhibitor, Nonapeptide-Converting; Nonapeptide Converting Enzyme Inhibitor; Peptide 9a, Bradykinin-Potentiating; Bradykinin potentiator B, 2-L-tryptophan-3-de-L-leucine-4-de-L-proline-8-L-glutamine-

Networked: 36 relevant articles (0 outcomes, 3 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Oligopeptides: 519
    - Teprotide: 36
      - GF 109: 1
      - GF 94

Related Diseases

1.	Hypertension (High Blood Pressure) 05/01/1981 - "Intrarenal infusion of teprotide resulted in vasodilatation during the first 3 days but failed to do so during the chronic phase of benign hypertension. " 02/01/1980 - "Long-term treatment with teprotide moderated the hypertension but had little effect on serum ACE activity or the responses to BK, AII, and AI. " 03/01/1982 - "With both R and LS diet, hypertension was associated with increased PRA (p less than 0.0005), and normotensive pressures were achieved with converting enzyme inhibitor (teprotide). " 11/01/1980 - "Cardiac output is increased by teprotide in patients with high-renin hypertension who exhibit the greatest decrements in peripheral resistance." 11/01/1984 - "Reduction in hypertension-induced protein synthesis in the rat pulmonary trunk after treatment with teprotide (SQ 20881)."
2.	Heart Failure 01/01/1986 - "Infusion of teprotide (an inhibitor of angiotensin I converting enzyme) returned the hemodynamic parameters to or toward values seen in rats without MI, thereby documenting an important role for angiotensin II in congestive heart failure." 11/01/1982 - "Coronary hemodynamic effects of angiotensin inhibition by captopril and teprotide in patients with congestive heart failure." 06/19/1980 - "Eight patients with severe congestive heart failure refractory to conventional therapy, including vasodilators, were given captopril (seven patients) or teprotide (one patient). " 11/01/1982 - "In 42 patients with moderate-to-severe congestive heart failure (CHF), the acute hemodynamic and neurohumoral response to the converting enzyme inhibitors (CEIs) captopril (CPT) and teprotide were measured. " 11/01/1982 - "The coronary hemodynamic effects of vasodilator therapy with angiotensin-converting enzyme inhibitors (captopril and teprotide) were studied in 11 patients with ischemic heart disease and severe congestive heart failure (CHF). "
3.	Body Weight (Weight, Body) 09/01/1980 - "In five studies in sodium-depleted monkeys, an infusion of 2 mg of the peptide per kg of body weight resulted in a reduction of mean arterial pressure (MAP) from 105 +/- 4 to 79 +/- 3 mm Hg, which is not significantly different from the response to 1 mg of the angiotensin I-converting enzyme inhibitor teprotide per kg. In uninephrectomized monkeys, inflation of a suprarenal aortic cuff caused an increase in MAP from 107 +/- 3 to 131 +/- 3 mm Hg. Infusion of 0.6 mg of the renin-inhibitory peptide per kg was followed by a return of blood pressure to 107 +/- 4 mm Hg--a depressor response similar to that observed with teprotide. "
4.	Essential Hypertension 05/31/1984 - "In patients with essential hypertension, in whom renal vascular tone is commonly increased, converting enzyme inhibitors such as teprotide and captopril induce a potentiated acute renal vascular response: renal blood flow increases more than it does in normal subjects. " 07/05/1979 - "To test the influence of an inhibitor of angiotensin-converting enzyme, teprotide (SQ 20881), we administered it to seven patients with essential hypertension and normal renal function and nine with an unequivocal reduction in creatinine clearance, caused by bilateral renal-artery stenosis in two and by essential hypertension in seven. " 04/21/1982 - "Angiotensin-converting enzyme inhibitors, both teprotide and captopril, induce a potentiated renal vascular response in patients with essential hypertension, and with that a consistent increase in sodium excretion and occasionally an increase in glomerular filtration rate. " 01/01/1982 - "2. Converting enzyme inhibitors, both teprotide and captopril, induce a potentiated renal vascular response in patients with essential hypertension, associated with a consistent increase in sodium excretion and occasionally an increase in glomerular filtration rate. " 06/01/1988 - "Converting-enzyme inhibition, whether teprotide, captopril, or enalapril is used, produces a larger increase in renal blood flow in patients with essential hypertension than in normal subjects when they are on a low-salt diet, a quantitative difference. "
5.	Renovascular Hypertension (Goldblatt Syndrome) 01/01/1988 - "The intrarenal kallikrein-kinin system was studied during the acute phase of renovascular hypertension induced by renal artery constriction and during teprotide inhibition of kininase II in the dog. " 03/16/1978 - "To determine its utility as an aid in diagnosis of renovascular hypertension, we administered nonapeptide converting-enzyme inhibitor (CEI) (which inhibits conversion of angiotensin I to angiotensin II) (0.25 mg per kilogram) to 14 unselected hypertensive patients undergoing bilateral renal-vein catheterization. " 08/01/1979 - "Baseline plasma renin activity and responses to saralasin and converting enzyme inhibitor SQ 20881 (teprotide) in 47 untreated patients with surgically correctable renovascular hypertension were compared to those in 100 patients with high- and normal-renin essential hypertension. "

Related Drugs and Biologics

1.	Enzyme Inhibitors (Inhibitors, Enzyme)
2.	Captopril (Capoten)
3.	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
4.	Renin
5.	Angiotensin II
6.	Sodium
7.	Saralasin (Saralasin Acetate)
8.	Enalapril
9.	Peptides (Polypeptides)
10.	renin inhibitory peptide

Related Therapies and Procedures

1.	Therapeutics
2.	Nephrectomy
3.	Sodium-Restricted Diet (Diet, Sodium Restricted)
4.	Aftercare (After-Treatment)